Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

250 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial.
Shiffman ML, Cheinquer H, Berg CP, Berg T, de Figueiredo-Mendes C, Dore GJ, Ferraz ML, Mendes-Corrêa MC, Lima MP, Parise ER, Rios AM, Reuter T, Sanyal AJ, Shafran SD, Hohmann M, Tatsch F, Bakalos G, Zeuzem S. Shiffman ML, et al. Among authors: reuter t. Hepatol Int. 2014 Oct;8(4):517-26. doi: 10.1007/s12072-014-9555-3. Epub 2014 Jul 24. Hepatol Int. 2014. PMID: 26202757
Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1-6 in Brazil.
Peribañez-Gonzalez M, Cheinquer H, Rodrigues L, Lima MP, Álvares-da-Silva MR, Madruga J, Parise ER, Pessoa MG, Furtado J, Villanova M, Ferreira A, Mazzoleni F, Nascimento E, Silva GF, Fredrick L, Krishnan P, Burroughs M, Reuter T. Peribañez-Gonzalez M, et al. Among authors: reuter t. Ann Hepatol. 2021 Jan-Feb;20:100257. doi: 10.1016/j.aohep.2020.09.002. Epub 2020 Sep 17. Ann Hepatol. 2021. PMID: 32949786 Free article. Clinical Trial.
The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study.
Ferreira PR, Silva MH, Brandão-Melo CE, Rezende RE, Gonzalez M, Reuter T, Urbaez JD, Gianini RJ, Martinelli A, Mendes-Correa MC. Ferreira PR, et al. Among authors: reuter t. Braz J Infect Dis. 2015 Jan-Feb;19(1):15-22. doi: 10.1016/j.bjid.2014.08.002. Epub 2014 Sep 1. Braz J Infect Dis. 2015. PMID: 25181403 Free PMC article.
Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus.
Grando AV, Ferreira PRA, Pessôa MG, Mazo DFC, Brandão-Mello CE, Reuter T, Martinelli ALC, Gonzalez MP, Nastri ACS, Campos AF, Lopes MIBF, Brito JDU, Mendes-Corrêa MC. Grando AV, et al. Among authors: reuter t. Rev Inst Med Trop Sao Paulo. 2017 Nov 6;59:e67. doi: 10.1590/S1678-9946201759067. Rev Inst Med Trop Sao Paulo. 2017. PMID: 29116287 Free PMC article.
Brazilian Society of Hepatology and Brazilian Society of Infectious Diseases Guidelines for the Diagnosis and Treatment of Hepatitis B.
Ferraz ML, Strauss E, Perez RM, Schiavon L, Kioko Ono S, Pessoa Guimarães M, Ferreira AP, Nabuco L, Carvalho-Filho R, Tovo C, Souto F, Abrão P, Reuter T, Dantas T, Vigani A, Porta G, Ferreira MS, Paraná R, Cimerman S, Bittencourt PL. Ferraz ML, et al. Among authors: reuter t. Braz J Infect Dis. 2020 Sep-Oct;24(5):434-451. doi: 10.1016/j.bjid.2020.07.012. Epub 2020 Sep 11. Braz J Infect Dis. 2020. PMID: 32926839 Free PMC article. Review.
Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study.
Callefi LA, Villela-Nogueira CA, de Barros Tenore S, Carnaúba-Júnior D, Coelho HSM, Pinto PTA, Nabuco LC, Pessoa MG, Ferraz MLCG, Ferreira PRA, de Lourdes Candolo Martinelli A, Chachá SGF, de Souza Paiva Ferreira A, de Macedo Bisio AP, Brandão-Mello CE, Álvares-Da-Silva MR, Reuter T, Ivantes CAP, de Mello Perez R, Mendes-Correa MCJ. Callefi LA, et al. Among authors: reuter t. Clinics (Sao Paulo). 2017 Jun;72(6):378-385. doi: 10.6061/clinics/2017(06)08. Clinics (Sao Paulo). 2017. PMID: 28658438 Free PMC article. Clinical Trial.
HEPATITIS C IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM: BURDEN OF DISEASE.
Castelo A, Mello CEB, Teixeira R, Madruga JVR, Reuter T, Pereira LMMB, Silva GF, Álvares-DA-Silva MR, Zambrini H, Ferreira PRA. Castelo A, et al. Among authors: reuter t. Arq Gastroenterol. 2018 Oct-Dec;55(4):329-337. doi: 10.1590/S0004-2803.201800000-74. Arq Gastroenterol. 2018. PMID: 30785514 Free article.
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.
Strategies for Management of Antiretroviral Therapy (SMART) Study Group; Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, et al. J Infect Dis. 2008 Apr 15;197(8):1145-55. doi: 10.1086/529523. J Infect Dis. 2008. PMID: 18476293 Clinical Trial.
Factors associated with D-dimer levels in HIV-infected individuals.
Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee. Borges AH, et al. PLoS One. 2014 Mar 13;9(3):e90978. doi: 10.1371/journal.pone.0090978. eCollection 2014. PLoS One. 2014. PMID: 24626096 Free PMC article.
250 results